LENZ Therapeutics (LENZ) Stock Price, News & Analysis

Company Overview

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Key Stats

• Today's Range: $22.34 to $23.47
• 50-Day Range: $22.36 to $37.37
• 52-Week Range: $14.42 to $38.93
• Volume: 143,402 shs
• Average Volume: 138,316 shs
• Market Capitalization: $618.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.40
• Consensus Rating: Buy

LENZ Therapeutics Stock Analysis - MarketRank™

LENZ Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 698th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

LENZ Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

LENZ Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for LENZ Therapeutics are expected to decrease in the coming year, from ($2.18) to ($2.54) per share.

Price to Book Value per Share Ratio

LENZ Therapeutics has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.31% of the float of LENZ Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

LENZ Therapeutics has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.

Change versus previous month

Short interest in LENZ Therapeutics has recently increased by 11.95%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LENZ Therapeutics does not currently pay a dividend.

Dividend Growth

LENZ Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.31% of the float of LENZ Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

LENZ Therapeutics has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.

Change versus previous month

Short interest in LENZ Therapeutics has recently increased by 11.95%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.93

News Sentiment

LENZ Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for LENZ Therapeutics this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for LENZ on MarketBeat in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LENZ Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

38.40% of the stock of LENZ Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LENZ Stock Analysis - Frequently Asked Questions

How have LENZ shares performed this year?

LENZ Therapeutics' stock was trading at $28.87 at the beginning of 2025. Since then, LENZ stock has decreased by 22.1% and is now trading at $22.50.
View the best growth stocks for 2025 here.

How were LENZ Therapeutics' earnings last quarter?

LENZ Therapeutics, Inc. (NASDAQ:LENZ) posted its earnings results on Wednesday, November, 6th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.09.

Who are LENZ Therapeutics' major shareholders?

LENZ Therapeutics' top institutional investors include Harbor Capital Advisors Inc. (0.16%), Kelleher Financial Advisors (0.06%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Ra Capital Management, LP and James W Mccollum.
View institutional ownership trends.

How do I buy shares of LENZ Therapeutics?

Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of LENZ Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LENZ Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 1/20/2025
• Next Earnings (Estimated): 2/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LENZ
• Previous Symbol: NASDAQ:LENZ
• CUSIP: N/A
• CIK: 1815776
• Web: www.graphitebio.com
• Phone: 650-484-0886
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $35.40
• High Stock Price Target: $38.00
• Low Stock Price Target: $32.00
• Potential Upside/Downside: +57.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-124,650,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -58.48%
• Return on Assets: -55.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 28.63
• Quick Ratio: 28.63

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $22.06 per share
• Price / Book: 1.02

Miscellaneous

• Outstanding Shares: 27,500,000
• Free Float: 16,941,000
• Market Cap: $618.75 million
• Optionable: N/A
• Beta: 0.57